BRKR Bruker Corporation

New APOLLO II Dual Source Incorporates Unique Two-stage Ion Funnel for Improved ESI and MALDI Sensitivity At Pittcon 2006, Bruker Daltonics today announces the new APOLLO(TM) II Dual Source for its apex(R) line of hybrid Q-q-FTMS mass spectrometers. The design of the new APOLLO II Dual Source is based on a wide aperture two-stage ion funnel with simultaneous integration of a MALDI and an ESI source. This unique design makes switching between ESI and MALDI instantaneous and trivial, while providing superior sensitivity for both modes of FTMS operation. The ESI and MALDI sources can even be operated simultaneously, enabling novel approaches to internal calibration. The apex-Qe is an easy-to-use, robust FTMS system for ultra-high performance life-science mass spectrometry. Its FTMS/MS sensitivity, resolution and mass accuracy are unparalleled. With the introduction of the APOLLO II Dual Source, Bruker Daltonics has now combined the high sensitivity performance of the ion funnel with the versatility and convenience of a dual ESI and MALDI source. Under ESI operation, the new source provides all the sensitivity improvements of the previously launched APOLLO II ESI source, specifically attomole levels of detection for on-column loading. This also translates into an overall increase in the speed of analysis as the FTMS analyzer can be filled more quickly with the high flux source. For MALDI, the APOLLO II Dual Source supports the industry standard MTP format with options of 96 and 384 spot targets, including the popular AnchorChip(TM) family of targets. The superior sensitivity performance of the MALDI source (attomole level sample loading) is facilitated by more efficient ion cooling, which has the additional benefit of enabling the use of a wider variety of matrices that can be tailored to specific applications. "It's going to have tremendous applications in improving mass accuracy and aiding proteomics research, especially in shotgun proteomics," said Dr. Jon Amster, Professor of Chemistry at the University of Georgia. The Amster Research Group in the Department of Chemistry uses the apex-Qe in their laboratory for the investigation of complex biological samples. Pittcon 2006, the 57th Pittsburgh Conference and Exposition on Analytical Chemistry and Applied Spectroscopy, will be held March 13-16 in Orlando, Florida in the Orange County Convention Center. Bruker Daltonics will exhibit at booth #3155. ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR) Bruker BioSciences, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker AXS is a leading developer and provider of life science, materials research and industrial X-ray analysis tools. For more information about Bruker BioSciences Corporation, please visit www.bruker-biosciences.com. CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the companies' reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the companies' products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K, our most recent quarterly reports on Form 10-Q, our current reports on Form 8-K and the joint proxy statement/prospectus filed in connection with the merger. We disclaim any intent or obligation to update these forward-looking statements.